Genophe Biotech Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
- Paid Up Capital ₹ 0.11 M
- Company Age 7 Year, 27 Days
- Last Filing with ROC 31 Mar 2024
- Revenue Growth -94.26%
- Profit Growth -102.58%
- Ebitda 82.29%
- Net Worth -68.96%
- Total Assets -20.14%
About Genophe Biotech
Genophe Biotech Private Limited (GBPL) is a registered startup operating as a Private Limited Indian Non-Government Company incorporated in India on 05 January 2018 (Seven years 27 days old ). Its registered office is in Bangaluru, Karnataka, India.
The Company is engaged in the Life Sciences Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.11 M, as per Ministry of Corporate Affairs (MCA) records.
Thiruneelakantan Srinath, Kalastauadi Baba, Kasi Rajgopal, and One other member serve as directors at the Company.
Company Details
-
Location
Bangaluru, Karnataka, India
-
Telephone
+91-XXXXXXXXXX
-
Email Address
-
Website
-
Social Media
Corporate Identity Details
-
CIN/LLPIN
U73200KA2018PTC109240
-
Company No.
109240
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
05 Jan 2018
-
Date of AGM
30 Sep 2024
-
Date of Balance Sheet
31 Mar 2024
-
Listing Status
Unlisted
-
ROC Code
Roc Bangalore
Industry
Who are the key members and board of directors at Genophe Biotech?
Board Members (4)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Thiruneelakantan Srinath
|
Director | 05-Jan-2018 | Current |
|
Kasi Rajgopal
|
Director | 12-Dec-2018 | Current |
|
Kalastauadi Baba
|
Director | 05-Oct-2018 | Current |
|
Geetika Singh
|
Director | 05-Aug-2020 | Current |
Financial Performance of Genophe Biotech.
Genophe Biotech Private Limited, for the financial year ended 2022, experienced significant reduction in revenue, with a 94.26% decrease. The company also saw a substantial fall in profitability, with a 102.58% decrease in profit. The company's net worth observed a substantial decline by a decrease of 68.96%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Genophe Biotech?
In 2022, Genophe Biotech had a promoter holding of 36.19% and a public holding of 63.81%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
-
Altanostics Labs Private LimitedThiruneelakantan Srinath is a mutual person
-
Zastraka Iron Castings Private LimitedKalastauadi Baba is a mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Genophe Biotech?
Unlock and access historical data on people associated with Genophe Biotech, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Genophe Biotech, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Genophe Biotech's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
